Zhaorong Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Zhaorong Li has a total of 271 co-authors. Here are the top co-authors by number of shared publications:
- Francisco J. Quintana
Ann Romney Center for Neurologic Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
17 shared publications - Aisha Saldanha
Dana-Farber Cancer Institute, Boston, Massachusetts
14 shared publications - Alessandro Leonetti
Medical Oncology Unit, University Hospital of Parma, Parma, Italy
14 shared publications - Antja-Voy Hartley
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts
14 shared publications - Audrey Mansuet-Lupo
Service d'anatomie pathologique, hôpital Cochin, 27, rue du faubourg Saint-Jacques, 75014 Paris, France
14 shared publications - Bishma Tuladhar
Dana-Farber Cancer Institute, Boston, Massachusetts
14 shared publications
Latest Publications
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Enrichment in embryonic epithelial signatures in osimertinib vs vehicle treated mice from Figure 1D.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Enrichment in embryonic epithelial signatures in osimertinib vs vehicle treated mice from Figure 1D.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Confirmation of TROP2 overexpression in surgical samples (n = 5 lobectomy, n = 1 pneumonectomy) of EGFR-mutant NSCLC after treatment with erlotinib, gefitinib or afatinib.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Confirmation of TROP2 overexpression in surgical samples (n = 5 lobectomy, n = 1 pneumonectomy) of EGFR-mutant NSCLC after treatment with erlotinib, gefitinib or afatinib.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Radiographic responses of Patients #2, #3 and #4.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Radiographic responses of Patients #2, #3 and #4.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Clinical characteristics of patients with EGFR-mutant NSCLC who received neoadjuvant EGFR-TKI followed by surgical resection.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Clinical characteristics of patients with EGFR-mutant NSCLC who received neoadjuvant EGFR-TKI followed by surgical resection.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S9 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TACSTD2 sequencing, hematoxylin and eosin staining and TROP2 IHC from in vivo relapsed tumors shown in Figure 4C in the sacituzumab govitecan group and the TROP2 CAR-T group.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S9 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TACSTD2 sequencing, hematoxylin and eosin staining and TROP2 IHC from in vivo relapsed tumors shown in Figure 4C in the sacituzumab govitecan group and the TROP2 CAR-T group.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TROP2 expression does not modulate osimertinib sensitivity and is not required for osimertinib DTP survival.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
TROP2 expression does not modulate osimertinib sensitivity and is not required for osimertinib DTP survival.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S8 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
BCMA and TROP2 CAR-T cell therapies efficacy versus sacituzumab govitecan in the DFCI-243 PDX model.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
BCMA and TROP2 CAR-T cell therapies efficacy versus sacituzumab govitecan in the DFCI-243 PDX model.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Transcriptional expression of ADC target genes and embryonic transcriptional signatures during residual disease state in EGFR mutated NSCLC samples.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Transcriptional expression of ADC target genes and embryonic transcriptional signatures during residual disease state in EGFR mutated NSCLC samples.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S11 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Immunohistochemistry for CAR-T demonstrates lack of persistence in relapsed tumors.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S11 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Immunohistochemistry for CAR-T demonstrates lack of persistence in relapsed tumors.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Table S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Amino acid sequence of domains used in CAR vector.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non–Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy
Amino acid sequence of domains used in CAR vector.